CASPAR – A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
A031902 pre-registration and registration is closed to new patient accrual, effective October 2, 2023.
A031902 is temporarily suspended to new patient registration (OPEN Step 2), effective May 10, 2023.
